These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31399272)

  • 1. Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.
    Miele GM; Caton L; Freese TE; McGovern M; Darfler K; Antonini VP; Perez M; Rawson R
    J Subst Abuse Treat; 2020 Jan; 108():20-25. PubMed ID: 31399272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary results of the evaluation of the California Hub and Spoke Program.
    Darfler K; Sandoval J; Pearce Antonini V; Urada D
    J Subst Abuse Treat; 2020 Jan; 108():26-32. PubMed ID: 31400985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. System-level factors shaping the implementation of "hub and spoke" systems to expand MOUD in rural areas.
    Snell-Rood C; Willging C; Showalter D; Peters H; Pollini RA
    Subst Abus; 2021; 42(4):716-725. PubMed ID: 33284083
    [No Abstract]   [Full Text] [Related]  

  • 5. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to treatment for opioid use disorders: Medical student preparation.
    McCance-Katz EF; George P; Scott NA; Dollase R; Tunkel AR; McDonald J
    Am J Addict; 2017 Jun; 26(4):316-318. PubMed ID: 28394437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 8. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing patterns of buprenorphine waivered physicians.
    Thomas CP; Doyle E; Kreiner PW; Jones CM; Dubenitz J; Horan A; Stein BD
    Drug Alcohol Depend; 2017 Dec; 181():213-218. PubMed ID: 29096292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania.
    Kawasaki S; Francis E; Mills S; Buchberger G; Hogentogler R; Kraschnewski J
    J Subst Abuse Treat; 2019 Nov; 106():58-64. PubMed ID: 31540612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding treatment for opioid use disorder in publicly funded primary care clinics: Exploratory evaluation of the NYC health + hospitals buprenorphine ECHO program.
    Tofighi B; Isaacs N; Byrnes-Enoch H; Lakew R; Lee JD; Berry C; Schatz D
    J Subst Abuse Treat; 2019 Nov; 106():1-3. PubMed ID: 31540604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to the special issue on innovative interventions and approaches to expand medication assisted treatment: Seizing research opportunities made available by the opioid STR program.
    Watson DP; Andraka-Christou B; Clarke T; Wiegandt J
    J Subst Abuse Treat; 2020 Jan; 108():1-3. PubMed ID: 31668689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opening the "black box": Four common implementation strategies for expanding the use of medications for opioid use disorder in primary care.
    Caton L; Shen H; Miele GM; Darfler K; Sandoval JR; Urada D; McGovern MP
    Implement Res Pract; 2021; 2():26334895211005809. PubMed ID: 37090014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
    Abraham AJ; Andrews CM; Grogan CM; Pollack HA; D'Aunno T; Humphreys K; Friedmann PD
    Psychiatr Serv; 2018 Apr; 69(4):448-455. PubMed ID: 29241428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes.
    Anderson JB; Martin SA; Gadomski A; Krupa N; Mullin D; Cahill A; Jenkins P
    Subst Abus; 2022; 43(1):222-230. PubMed ID: 34086529
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 19. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
    Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
    Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.